Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05966753 · ClinicalTrials.gov registry record
Describing Patient With DME, Their Patient Journey and Disease Progression
A clinical trial of Diabetic Macular Edema, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 221,004
- Enrollment target
- 1
- Study location
NCT05966753: Completed study of Diabetic Macular Edema, sponsored by Boehringer Ingelheim.
NCT05966753 is a study of Diabetic Macular Edema that has completed, run by Boehringer Ingelheim. The registered enrollment target is 221,004 participants, above the 286-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (77174% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05966753, a study of Diabetic Macular Edema, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 221,004 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to characterize patients with diabetic macular edema (DME), their progression, the treatment received and associate the functional and physiological outcomes related to the treatment.
Conditions Studied
Study Locations (1)
Massachusetts
- CorEvitas HQ - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221,004 participants |
| Start Date | 2023-08-03 |
| Est. Completion | 2023-12-31 |
What the finished NCT05966753 record still lists
NCT05966753 is an observational study that tracks outcomes without assigning an intervention. Its 221,004 participants enrollment target places it among the larger protocols in the corpus, above the 286-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (77174% higher).
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 0 interventions.
NCT05966753 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05966753 about?
NCT05966753 is a clinical study titled "Describing Patient With DME, Their Patient Journey and Disease Progression". This study aims to characterize patients with diabetic macular edema (DME), their progression, the treatment received and associate the functional and physiological outcomes related to the treatment.
What is the current status of trial NCT05966753?
This trial is currently completed. The enrollment target is 221,004 participants. The study started on 2023-08-03. Estimated completion is 2023-12-31.
What conditions does trial NCT05966753 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
Who is sponsoring clinical trial NCT05966753?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05966753 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05966753's enrollment target sits among peer trials
221,004 1st of 63 higher than 63 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
RECRUITING · Phase 3
-
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04735835 · 250,000 participants · NA
Personalized Responses to Dietary Composition Trial 3
- NCT06090578 · 180,000 participants · NA
TabCAT Brain Health Assessment in Primary Care
- NCT06917339 · 156,000 participants
Retrospective Analyses of TrakStar Database
- NCT06232551 · 152,000 participants · NA
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI